EN
Jupiter Life Line Hospitals Limited Just Missed EPS By 76%: Here's What Analysts Think Will Happen Next
It's been a good week for Jupiter Life Line Hospitals Limited (NSE:JLHL) shareholders, because the company has just released its latest quarterly results, and the shares gained 5.0% to ₹256. Statutory earnings per share fell badly short of expectations, coming in at ₹1.72, some 76% below analyst forecasts, although revenues were okay, approximately in line with analyst estimates at ₹4.6b. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
After the latest results, the six analysts covering Jupiter Life Line Hospitals are now predicting revenues of ₹17.9b in 2027. If met, this would reflect a solid 11% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 4.0% to ₹5.92. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹17.9b and earnings per share (EPS) of ₹6.46 in 2027. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.
View our latest analysis for Jupiter Life Line Hospitals
The average price target fell 7.3% to ₹321, with reduced earnings forecasts clearly tied to a lower valuation estimate. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Jupiter Life Line Hospitals at ₹350 per share, while the most bearish prices it at ₹275. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Jupiter Life Line Hospitals is an easy business to forecast or the the analysts are all using similar assumptions.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Jupiter Life Line Hospitals' growth to accelerate, with the forecast 23% annualised growth to the end of 2027 ranking favourably alongside historical growth of 16% per annum over the past three years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 19% per year. Jupiter Life Line Hospitals is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Jupiter Life Line Hospitals' future valuation.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Jupiter Life Line Hospitals analysts - going out to 2029, and you can see them free on our platform here.
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Jupiter Life Line Hospitals that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.